Cardiology · Atrial FibrillationTrial Updateclinicalmid-term

Registry Launched to Evaluate Farapulse PFA Technology for Atrial Fibrillation

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/26/2026, 6:30:58 AM

Assessment confidence: 49% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The launch of the DISRUPT-AF Registry is significant as it aims to collect real-world data on the Farapulse technology, which could shape treatment guidelines and influence market dynamics in the atrial fibrillation space. Monitoring the outcomes will be crucial for understanding competitive positioning and potential shifts in market share. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 9 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should monitor outcomes from this registry to assess the potential impact on market share and treatment guidelines for AF. The strongest clinical anchor is Novel Model of Integrated Care of Older Patients With Atrial Fibrillation and Heart Failure in Rural China (MIRACLE-AFHF) (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 3 regulatory and 2 competitive items passed relevance filtering for Farapulse.

Competitive Pressure

The most relevant competitive pressure comes from Lilly's retatrutide shows significant weight loss in Phase 3 obesity trials (Humanexa Signals) — sponsor/company relevance (lilly). Secondary pressure from Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials. This registry may provide critical data that could influence the adoption and competitive positioning of Farapulse technology against other AF treatment options.

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). Relevant agencies in corpus: FDA, MHRA. Findings from the registry could lead to new regulatory submissions, potentially affecting the approval and labeling of the Farapulse system.

Key Risks

Elevated medium regulatory exposure for Farapulse could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Farapulse through agency review timelines and labeling constraints if follow-through weakens.
Regulatory risk from MHRA (Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension) could weigh on Farapulse through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

The data gathered may enhance the adoption of Farapulse technology, impacting revenue streams and market share against established AF treatment options.
Upside for Farapulse may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Portfolio teams should monitor outcomes from this registry to assess the potential impact on market share and treatment guidelines for AF.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results from the registry and any subsequent regulatory submissions based on the findings.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
MHRAhigh relevance
Sub-indication match (cardiology)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Novel Model of Integrated Care of Older Patients With Atrial Fibrillation and Heart Failure in Rural China (MIRACLE-AFHF)
ClinicalTrials.govmedium relevance
Sub-indication match (cardiology)
FDA document
View source
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
ClinicalTrials.govmedium relevance
Entity match (farapulse)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA
ClinicalTrials.govmedium relevance
Entity match (farapulse)
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Evaluation of the Safety and Effectiveness of the CORUS™ Posterior Cervical Stabilization System 3D (PCSS 3D) for the Treatment of 2-level Cervical Degenerative Disease
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Lilly's retatrutide shows significant weight loss in Phase 3 obesity trials
Humanexa Signalsmedium relevance
Sponsor/company relevance (Lilly)
Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)
Nanovaccines Show Superior Efficacy Over Ampicillin in Preventing Neonatal Listeriosis
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Farapulse
Atrial Fibrillation treatment market

Commercial impact

medium

The data gathered may enhance the adoption of Farapulse technology, impacting revenue streams and market share against established AF treatment options.

Regulatory impact

medium

Findings from the registry could lead to new regulatory submissions, potentially affecting the approval and labeling of the Farapulse system.

What to watch

Key milestones include interim results from the registry and any subsequent regulatory submissions based on the findings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.